University of Kiel

Ceramic Fiber Market Worth USD 4432.5 Million by 2028 at a CAGR of 9.8% - Report by Brandessence Market Research

Retrieved on: 
Monday, October 31, 2022

Mechanical and chemical recycling processes such as solvolysis and pyrolysis is performed to produce three new products: glass fiber, carbon fiber and glycols.

Key Points: 
  • Mechanical and chemical recycling processes such as solvolysis and pyrolysis is performed to produce three new products: glass fiber, carbon fiber and glycols.
  • Glass fiber will be applied in the form of ceramic supports, frits and glazes to reduce tile firing temperature.
  • Inks will be manufactured with the glycols and carbon fiber will be used to make sustainable composites for the transport sector.
  • Register for free trial here at https://brandessenceresearch.com/i-factor/login/userRegister
    Brandessence Market Research & Consulting Pvt ltd.
    Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts.

DGAP-News: APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill

Retrieved on: 
Thursday, September 1, 2022

The SECURE study and its results were published in the prestigious New England Journal of Medicine concurrent with its presentation at the Congress.

Key Points: 
  • The SECURE study and its results were published in the prestigious New England Journal of Medicine concurrent with its presentation at the Congress.
  • Prof. Dr. Burkhard Weisser (Kiel, Germany) presented the results of the add-on analysis to the START study conducted in Germany.
  • SECURE and START are the proof of principle of the Single Pill concept in a prospective study.
  • Since 2013, APONTIS PHARMA successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention.

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

Retrieved on: 
Tuesday, May 17, 2022

IN8bio will hold a webcast R&D Workshop on May 17, 2022 at 6:00 p.m. EDT to discuss the new platform.

Key Points: 
  • IN8bio will hold a webcast R&D Workshop on May 17, 2022 at 6:00 p.m. EDT to discuss the new platform.
  • NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced data emerging from the Companys recently unveiled iPSC-based gamma-delta T cell platform.
  • Our iPSC program is innovative and could provide a potentially unlimited off-the-shelf source of gamma-delta T cells, said Lawrence Lamb Ph.D., CSO, and co-founder of IN8bio.
  • IN8bio presented data from the iPSC platform during both podium and poster presentations at the ASGCT 25th Annual Meeting in Washington, DC, on May 16, 2022.

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia

Retrieved on: 
Monday, December 13, 2021

OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.

Key Points: 
  • OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.
  • Despite the favourable prognosis of BCP-ALL, relapse remains a clinical challenge and novel targeted immunotherapy options are urgently needed.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, December 10, 2021

Cibinqo also demonstrated a consistent safety profile across trials, including in a long-term extension study, showing a favorable benefit-risk profile.

Key Points: 
  • Cibinqo also demonstrated a consistent safety profile across trials, including in a long-term extension study, showing a favorable benefit-risk profile.
  • Findings from the following five studies in the Cibinqo JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program were included in the submission to support this approval.
  • The study also included an active control arm with dupilumab, a biologic treatment administered by subcutaneous injection, compared with placebo.
  • ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.

AGCO Appoints Niels Pörksen to Its Board of Directors

Retrieved on: 
Thursday, October 21, 2021

AGCO, Your Agriculture Company, (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural machinery and precision ag technology, announced today the election of Niels Prksen to its Board of Directors effective October 21, 2021.

Key Points: 
  • AGCO, Your Agriculture Company, (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural machinery and precision ag technology, announced today the election of Niels Prksen to its Board of Directors effective October 21, 2021.
  • We are delighted to have Niels join our Board, said Eric Hansotia, Chairman, President and CEO of AGCO Corporation.
  • Roy Armes is retiring from the Board of Directors effective October 21, 2021.
  • Roy has made an extraordinary contribution to AGCO and its Board and we are extremely grateful for Roys guidance and leadership over the years, Mr. Hansotia added.

Benchmark Genome Study Demonstrates Accuracy of Artificial Intelligence in Rapidly Diagnosing Rare Diseases in Critically Ill Patients

Retrieved on: 
Thursday, October 14, 2021

In addition, Fabric GEM ranked specific diseases and conditions associated with these genes to assist clinicians in the ultimate diagnosis of each case.

Key Points: 
  • In addition, Fabric GEM ranked specific diseases and conditions associated with these genes to assist clinicians in the ultimate diagnosis of each case.
  • These findings demonstrate how artificial intelligence (AI) can successfully reduce the burden of gene variant review by clinical geneticists.
  • This study provides the rigorous benchmark validation required for its use in the clinic, showcasing how any hospital can bring informed genomics to their patients.
  • The complete study, titled Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases , can be accessed on the Genome Medicine website.